{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:53:14Z","timestamp":1762782794333,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ymgme.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T02:24:36Z","timestamp":1661221476000},"page":"173-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Agalsidase-\u03b2 should be proposed as first line therapy in classic male Fabry patients with undetectable \u03b1-galactosidase A activity"],"prefix":"10.1016","volume":"137","author":[{"given":"Albina","family":"Nowak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Dormond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Monzambani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uyen","family":"Huynh-Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2022.08.003_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147663","article-title":"X chromosome inactivation in carriers of fabry disease: review and meta-analysis","volume":"22","author":"Viggiano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0040","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Nino","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0045","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0050","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"Shabbeer","year":"2006","journal-title":"Hum Genomics"},{"key":"10.1016\/j.ymgme.2022.08.003_bb0065","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2022.08.003_bb0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0075","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2022.08.003_bb0100","first-page":"95","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for fabry disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/jmedgenet-2020-106874","article-title":"Treatment switch in Fabry disease- a matter of dose?","volume":"58","author":"Lenders","year":"2021","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0115","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1681\/ASN.2015030337","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction and Switch-2-year follow-up","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2017.09.027","article-title":"Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up","volume":"249","author":"Siegenthaler","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0140","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0150","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0155","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gim.2016.117","article-title":"Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature","volume":"19","author":"Pisani","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2022.08.003_bb0165","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1517\/14728222.11.6.821","article-title":"Novel therapeutic targets for the treatment of Fabry disease","volume":"11","author":"Hollak","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymgme.2022.08.003_bb0170","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0175","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0180","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/jmedgenet-2020-107162","article-title":"Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort","volume":"58","author":"Effraimidis","year":"2021","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0185","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0195","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent Agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0200","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages","volume":"33","author":"Kramer","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10557-009-6177-4","article-title":"Cardiovascular and renal surrogate markers in the clinical management of hypertension","volume":"23","author":"Maisel","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ymgme.2022.08.003_bb0210","doi-asserted-by":"crossref","first-page":"BIO27","DOI":"10.1167\/iovs.17-21778","article-title":"Biomarkers and surrogate endpoints in drug development: a European regulatory view","volume":"58","author":"Wickstrom","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222003900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222003900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:54:35Z","timestamp":1761090875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719222003900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":42,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1096719222003900"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.08.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agalsidase-\u03b2 should be proposed as first line therapy in classic male Fabry patients with undetectable \u03b1-galactosidase A activity","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}